NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Forecast, Price & News $5.20 0.00 (0.00%) (As of 01:02 PM ET) Add Compare Share Share Today's Range$5.05▼$5.3050-Day Range$5.18▼$9.0952-Week Range$5.04▼$43.20Volume11,664 shsAverage Volume81,650 shsMarket Capitalization$5.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Quoin Pharmaceuticals (NASDAQ:QNRX) StockQuoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.Read More QNRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNRX Stock News HeadlinesSeptember 16, 2023 | americanbankingnews.comQuoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.9%August 9, 2023 | finance.yahoo.comQuoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for ShareholdersSeptember 21, 2023 | Chaikin Analytics (Ad)Wall Street Legend Warns "Mass Bank Run" is ComingMan who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.August 3, 2023 | msn.comQuoin Pharmaceuticals Ltd - ADR (QNRX) Price Target Increased by 1423.07% to 134.64July 27, 2023 | finance.yahoo.comQuoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ETJuly 21, 2023 | benzinga.comWhat's Going On With Quoin Pharmaceuticals (QNRX) Stock Today?July 17, 2023 | msn.comWhy Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today?July 17, 2023 | msn.comWhy Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?September 21, 2023 | Chaikin Analytics (Ad)Wall Street Legend Warns "Mass Bank Run" is ComingMan who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.May 24, 2023 | finance.yahoo.comQuoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical TrialMay 12, 2023 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial ResultsMay 8, 2023 | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial ResultsMay 5, 2023 | msn.comA Preview Of Quoin Pharmaceuticals's EarningsMay 2, 2023 | finance.yahoo.comQuoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ETMarch 22, 2023 | finance.yahoo.comQNRX: Patients Dosed in Both Concurrent Studies; Potentially Adding New Assets to Product PortfolioMarch 21, 2023 | finance.yahoo.comQuoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical TrialMarch 11, 2023 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 8, 2023 | msn.comQuoin Pharmaceuticals GAAP EPS of -$0.41 beats by $0.19March 2, 2023 | finance.yahoo.comQuoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ETMarch 1, 2023 | finance.yahoo.comA Pivotal Year Ahead for Quoin PharmaceuticalsFebruary 24, 2023 | seekingalpha.comQuoin Pharmaceuticals plunge 45% on pricing $7M stock offeringFebruary 22, 2023 | msn.comWhy Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionFebruary 22, 2023 | benzinga.comWhy Quoin Pharmaceuticals Shares Are Getting Obliterated WednesdayFebruary 22, 2023 | finance.yahoo.comQuoin Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingDecember 13, 2022 | finance.yahoo.comQuoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton SyndromeDecember 5, 2022 | finance.yahoo.comQNRX: Moving QRX003 Forward in Concurrent StudiesSee More Headlines Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address QNRX Company Calendar Last Earnings8/02/2023Today9/21/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QNRX CUSIPN/A CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($22.4186) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.57% Return on Assets-58.99% Debt Debt-to-Equity RatioN/A Current Ratio3.55 Quick Ratio3.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$18.35 per share Price / Book0.28Miscellaneous Outstanding Shares980,000Free Float956,000Market Cap$5.10 million OptionableNot Optionable Beta1.82 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Michael Myers Ph.D. (Age 61)Co-Founder, CEO & Chairman Comp: $607.11kMs. Denise Carter (Age 54)Co-Founder, COO & Director Comp: $585.22kMr. Gordon Bruce Dunn J.D. (Age 59)Chief Financial Officer Comp: $361.38kKey CompetitorsNeuroMetrixNASDAQ:NUROFemasysNASDAQ:FEMYGlucoTrackNASDAQ:GCTKPolyPidNASDAQ:PYPDAethlon MedicalNASDAQ:AEMDView All Competitors QNRX Stock - Frequently Asked Questions Should I buy or sell Quoin Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" QNRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QNRX, but not buy additional shares or sell existing shares. View QNRX analyst ratings or view top-rated stocks. How have QNRX shares performed in 2023? Quoin Pharmaceuticals' stock was trading at $17.04 at the start of the year. Since then, QNRX stock has decreased by 69.5% and is now trading at $5.20. View the best growth stocks for 2023 here. Are investors shorting Quoin Pharmaceuticals? Quoin Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 9,300 shares, a decrease of 30.6% from the August 15th total of 13,400 shares. Based on an average daily volume of 158,600 shares, the short-interest ratio is presently 0.1 days. View Quoin Pharmaceuticals' Short Interest. When is Quoin Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our QNRX earnings forecast. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($2.13) earnings per share for the quarter. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals shares reverse split before market open on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Quoin Pharmaceuticals' stock symbol? Quoin Pharmaceuticals trades on the NASDAQ under the ticker symbol "QNRX." How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Quoin Pharmaceuticals' stock price today? One share of QNRX stock can currently be purchased for approximately $5.20. How much money does Quoin Pharmaceuticals make? Quoin Pharmaceuticals (NASDAQ:QNRX) has a market capitalization of $5.10 million. The company earns $-9,380,000.00 in net income (profit) each year or ($22.4186) on an earnings per share basis. How can I contact Quoin Pharmaceuticals? Quoin Pharmaceuticals' mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The official website for the company is quoinpharma.com. The company can be reached via phone at (703) 980-4182, via email at ir@cellectbio.com, or via fax at 972-9767-8750. This page (NASDAQ:QNRX) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.